AsiDNA
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AsiDNA, covering 2024-09-19 to 2024-12-05. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months [Phase 1, Phase 2]